Dinaciclib | List of Frontiers open access articles

Original Research

Published on 25 Nov 2022

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

in Gynecological Oncology

David Howard
David James
Jezabel Garcia-Parra
Belen Pan-Castillo
Jenny Worthington
Nicole Williams
Zoe Coombes
Sophie Colleen Rees
Kerryn Lutchman-Singh
Lewis W. Francis

Frontiers in Oncology

doi 10.3389/fonc.2022.1014280

5,825 views
14 citations

Original Research

Published on 07 Jan 2025

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML

in Hematologic Malignancies

Petra Bašová
Lubomír Minařík
Silvia Carina Magalhaes-Novais
Jana Balounová
Zuzana Zemanová
Tatiana Aghová
Martin Špaček
Anna Jonášová
Kristýna Gloc Pimková
Jan Procházka

Frontiers in Oncology

doi 10.3389/fonc.2024.1414950

4,451 views

Original Research

Published on 21 Sep 2023

The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress

in Pharmacology of Anti-Cancer Drugs

Xuefeng Lv
Yanyan Jia
Jinpeng Li
Shu Deng
Enwu Yuan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1234181

3,191 views
3 citations

Original Research

Published on 14 Feb 2020

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib

in Cancer Immunity and Immunotherapy

Christin Riess
Björn Schneider
Hanna Kehnscherper
Julia Gesche
Nina Irmscher
Fatemeh Shokraie
Carl Friedrich Classen
Elisa Wirthgen
Grazyna Domanska
Annette Zimpfer

Frontiers in Immunology

doi 10.3389/fimmu.2020.00055

11,605 views
36 citations

Original Research

Published on 10 Jun 2024

Unveiling Immune-related feature genes for Alzheimer’s disease based on machine learning

in Multiple Sclerosis and Neuroimmunology

Guimei Zhang
Shuo Sun
Yingying Wang
Yang Zhao
Li Sun

Frontiers in Immunology

doi 10.3389/fimmu.2024.1333666

4,963 views
3 citations

Original Research

Published on 08 Apr 2025

Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1

in Immunological Tolerance and Regulation

Shira Hagbi-Levi
Michal Abraham
Lika Gamaev
Inbal Mishaelian
Ophir Hay
Elina Zorde-Khevalevsky
Ori Wald
Hanna Wald
Devorah Olam
Lola Weiss

Frontiers in Immunology

doi 10.3389/fimmu.2025.1502094

2,843 views
1 citation

Articles

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML

The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib

Unveiling Immune-related feature genes for Alzheimer’s disease based on machine learning

Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1